Verrica Pharmaceuticals (VRCA) Competitors $0.64 +0.01 (+1.93%) As of 10:46 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA vs. DRUG, CRGX, IPHA, NBTX, TIL, SOPH, BTMD, KOD, NVCT, and INBXShould you be buying Verrica Pharmaceuticals stock or one of its competitors? The main competitors of Verrica Pharmaceuticals include Bright Minds Biosciences (DRUG), CARGO Therapeutics (CRGX), Innate Pharma (IPHA), Nanobiotix (NBTX), Instil Bio (TIL), SOPHiA GENETICS (SOPH), biote (BTMD), Kodiak Sciences (KOD), Nuvectis Pharma (NVCT), and Inhibrx (INBX). These companies are all part of the "pharmaceutical products" industry. Verrica Pharmaceuticals vs. Its Competitors Bright Minds Biosciences CARGO Therapeutics Innate Pharma Nanobiotix Instil Bio SOPHiA GENETICS biote Kodiak Sciences Nuvectis Pharma Inhibrx Bright Minds Biosciences (NASDAQ:DRUG) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, community ranking, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Is DRUG or VRCA more profitable? Bright Minds Biosciences has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -625.06%. Bright Minds Biosciences' return on equity of -5.85% beat Verrica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Bright Minds BiosciencesN/A -5.85% -5.68% Verrica Pharmaceuticals -625.06%-591.84%-141.63% Which has more volatility and risk, DRUG or VRCA? Bright Minds Biosciences has a beta of -5.75, indicating that its share price is 675% less volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Do insiders & institutionals believe in DRUG or VRCA? 40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 42.6% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer DRUG or VRCA? Verrica Pharmaceuticals received 156 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users. However, 91.67% of users gave Bright Minds Biosciences an outperform vote while only 62.78% of users gave Verrica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBright Minds BiosciencesOutperform Votes1191.67% Underperform Votes18.33%Verrica PharmaceuticalsOutperform Votes16762.78% Underperform Votes9937.22% Do analysts rate DRUG or VRCA? Bright Minds Biosciences presently has a consensus target price of $83.25, indicating a potential upside of 192.62%. Verrica Pharmaceuticals has a consensus target price of $8.00, indicating a potential upside of 1,159.84%. Given Verrica Pharmaceuticals' higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than Bright Minds Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bright Minds Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has preferable valuation & earnings, DRUG or VRCA? Bright Minds Biosciences has higher earnings, but lower revenue than Verrica Pharmaceuticals. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBright Minds BiosciencesN/AN/A-$2.06M-$0.36-79.03Verrica Pharmaceuticals$7.18M8.18-$67M-$1.20-0.53 Does the media refer more to DRUG or VRCA? In the previous week, Bright Minds Biosciences had 2 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 3 mentions for Verrica Pharmaceuticals. Verrica Pharmaceuticals' average media sentiment score of 1.15 beat Bright Minds Biosciences' score of 1.13 indicating that Verrica Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verrica Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBright Minds Biosciences beats Verrica Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRCA vs. The Competition Export to ExcelMetricVerrica PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.73M$6.93B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.358.8527.2320.02Price / Sales8.18256.44417.65154.33Price / CashN/A65.8538.2534.64Price / Book1.356.617.124.70Net Income-$67M$143.93M$3.23B$247.97M7 Day Performance8.83%3.84%2.74%2.64%1 Month Performance25.42%11.14%8.94%6.39%1 Year Performance-92.60%4.35%31.59%13.95% Verrica Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRCAVerrica Pharmaceuticals4.4574 of 5 stars$0.64+1.9%$8.00+1,159.8%-93.0%$58.73M$7.18M-0.3540Positive NewsShort Interest ↓DRUGBright Minds Biosciences3.3439 of 5 stars$28.32+9.1%$83.25+194.0%+2,469.4%$199.49MN/A-166.58N/APositive NewsAnalyst RevisionCRGXCARGO Therapeutics2.4275 of 5 stars$4.28+0.7%$15.00+250.5%-74.2%$197.35MN/A-1.00116Positive NewsIPHAInnate Pharma3.2977 of 5 stars$2.14-2.2%$11.00+413.8%-22.5%$197.35M$12.62M0.00220Positive NewsGap DownNBTXNanobiotix2.894 of 5 stars$4.13+0.8%$8.00+93.5%-12.7%$194.85M-$11.61M0.00100News CoveragePositive NewsShort Interest ↓TILInstil Bio2.6619 of 5 stars$29.65+10.0%$112.33+278.9%+237.3%$194.47MN/A-2.56410Short Interest ↑High Trading VolumeSOPHSOPHiA GENETICS1.8284 of 5 stars$2.91-3.0%$6.80+133.7%-38.1%$194.06M$67.17M-2.67520News CoverageGap DownBTMDbiote3.7258 of 5 stars$3.54+2.3%$8.00+126.0%-35.4%$193.67M$199.38M13.62194KODKodiak Sciences4.3331 of 5 stars$3.60+5.9%$9.00+150.0%+42.9%$189.95MN/A-0.9990Short Interest ↓NVCTNuvectis Pharma2.8268 of 5 stars$8.98-4.6%$17.00+89.3%+33.2%$187.63MN/A-7.748Positive NewsINBXInhibrx3.108 of 5 stars$12.96-3.8%N/A-12.8%$187.61M$200K0.11166Positive NewsUpcoming Earnings Related Companies and Tools Related Companies DRUG Alternatives CRGX Alternatives IPHA Alternatives NBTX Alternatives TIL Alternatives SOPH Alternatives BTMD Alternatives KOD Alternatives NVCT Alternatives INBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRCA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRCA Stock Free VRCA Stock Alerts